DelveInsight’s ‘Fanconi Anemia – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Fanconi anemia in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Fanconi Anemia Key Highlights
Key Companies working in the Fanconi Anemia market include Rocket Pharmaceuticals, Foresee Pharmaceuticals, and many others.
Key Therapies included in the Fanconi Anemia market include RP-L102, FP-045, and many others
Fanconi Anemia Overview
As per the National Cancer Institute (NCI), Fanconi anemia is a rare inherited disorder in which the bone marrow does not make enough blood cells, including red blood cells, white blood cells, and platelets. It is usually diagnosed before the age of 15 years.
Symptoms include frequent infections, a tendency to bleed easily, and extreme tiredness. People with Fanconi anemia may also have brown spots on the skin, short height, malformed thumbs or forearms, small heads or eyes, hearing loss, and abnormalities of the kidneys, gastrointestinal tract, heart, genitals, brain, and spinal cord. They also have an increased risk of developing certain types of cancer, including leukemia and cancers of the skin, head, neck, gastrointestinal system, and genitals. Fanconi anemia is caused by mutations (changes) in certain genes involved in DNA repair.
An early and accurate diagnosis of Fanconi anemia is often difficult because Fanconi anemia is highly variable genetically and in how it presents in each individual. The following methods are used in diagnosing Fanconi anemia: history and examination, tests and assessments, Fanconi anemia complementation/genetic analysis, skin biopsy, bone marrow examination, imaging, and related tests.
Fanconi Anemia Epidemiology Insights
Fanconi anemia is a very rare type of anemia. Overall, an average of 1 out of 136000 newborns has Fanconi anemia, and it varies from 1 in 100000 to 250000 births.
The male-to-female ratio in the literature cases is 1.2:1, although equal numbers are expected in a disorder with over 99% autosomal recessive inheritance.
Fanconi anemia has been diagnosed in patients from birth to age 49 years, with a median age of 7 years. Individuals with birth defects are diagnosed at younger ages than are persons without birth defects.
Click here to learn more about the Fanconi Anemia Market Landscape
The Report Covers the Fanconi Anemia Epidemiology Segmented by:
Fanconi Anemia prevalent cases
Fanconi Anemia incident cases
Fanconi Anemia treatment cases
Fanconi Anemia diagnosed cases
Fanconi Anemia Market Outlook
The Fanconi anemia market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Fanconi anemia market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. This segment gives a thorough detail of the Fanconi anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. As per DelveInsight, the Fanconi anemia market in the 7MM is expected to change in 2019–2032.
Key Companies Working in the Fanconi Anemia Market
Rocket Pharmaceuticals
Foresee Pharmaceuticals
And many others
Fanconi Anemia Therapies Covered and Analyzed in the Report
RP-L102
FP-045
Learn more about the Key Companies and Emerging Therapies in the Fanconi Anemia Market
Table of Contents
Key Insights
Fanconi Anemia Introduction
Executive Summary of Fanconi Anemia
Disease Background and Overview
Epidemiology and patient population
Fanconi Anemia Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Fanconi Anemia Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services